Comparative effectiveness of 4 natural and chemical activators of Nrf2 on inflammation, oxidative stress, macrophage polarization, and bactericidal activity in an in vitro macrophage infection model.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 17 12 2019
accepted: 27 05 2020
entrez: 9 6 2020
pubmed: 9 6 2020
medline: 1 9 2020
Statut: epublish

Résumé

Inflammation plays a crucial role in the defense response of the innate immune system against pathogen infection. In this study, we selected 4 compounds for their potential or proven anti-inflammatory and/or anti-microbial properties to test on our in vitro model of bacteria-infected THP-1-derived macrophages. We first compared the capacity of sulforaphane (SFN), wogonin (WG), oltipraz (OTZ), and dimethyl fumarate (DMF) to induce the nuclear factor erythroid 2-related factor 2 (Nrf2), a key regulator of the antioxidant, anti-inflammatory response pathways. Next, we performed a comparative evaluation of the antioxidant and anti-inflammatory efficacies of the 4 selected compounds. THP-1-derived macrophages and LPS-stimulated macrophages were treated with each compound and expression levels of genes coding for inflammatory cytokines IL-1β, IL-6, and TNF-α were quantified by RT-qPCR. Moreover, expression levels of genes coding for M1 (IL-23, CCR7, IL-1β, IL-6, and TNF-α) and M2 (PPARγ, MRC1, CCL22, and IL-10) markers were determined in classically-activated M1 macrophages treated with each compound. Finally, the effects of each compound on the intracellular bacterial survival of gram-negative E. coli and gram-positive S. aureus in THP-1-derived macrophages and PBMC-derived macrophages were examined. Our data confirmed the anti-inflammatory and antioxidant effects of SFN, WG, and DMF on LPS-stimulated THP-1-derived macrophages. In addition, SFN or WG treatment of classically-activated THP-1-derived macrophages reduced expression levels of M1 marker genes, while SFN or DMF treatment upregulated the M2 marker gene MRC1. This decrease in expression of M1 marker genes may be correlated with the decrease in intracellular S. aureus load in SFN- or DMF-treated macrophages. Interestingly, an increase in intracellular survival of E. coli in SFN-treated THP-1-derived macrophages that was not observed in PBMC-derived macrophages. Conversely, OTZ exhibited pro-oxidant and proinflammatory properties, and affected intracellular survival of E. coli in THP-1-derived macrophages. Altogether, we provide new potential therapeutic alternatives in treating inflammation and bacterial infection.

Identifiants

pubmed: 32511271
doi: 10.1371/journal.pone.0234484
pii: PONE-D-19-34877
pmc: PMC7279588
doi:

Substances chimiques

Anti-Inflammatory Agents 0
Antioxidants 0
Flavanones 0
Isothiocyanates 0
NF-E2-Related Factor 2 0
NFE2L2 protein, human 0
Pyrazines 0
Sulfoxides 0
Thiones 0
Thiophenes 0
oltipraz 6N510JUL1Y
Dimethyl Fumarate FO2303MNI2
sulforaphane GA49J4310U
wogonin POK93PO28W

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0234484

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Pharmacol Res. 2018 Jul;133:218-235
pubmed: 29391237
J Immunol. 2016 Oct 1;197(7):2864-79
pubmed: 27566827
J Immunol. 2010 Jul 1;185(1):569-77
pubmed: 20511556
Antioxid Redox Signal. 2017 May 10;26(14):748-762
pubmed: 26914345
Nat Rev Immunol. 2003 Jan;3(1):23-35
pubmed: 12511873
Front Genet. 2012 Jan 24;3:7
pubmed: 22303412
Nat Commun. 2016 May 23;7:11624
pubmed: 27211851
Antimicrob Agents Chemother. 2003 Jul;47(7):2283-92
pubmed: 12821480
Brain. 2011 Mar;134(Pt 3):678-92
pubmed: 21354971
Free Radic Biol Med. 2017 May;106:288-301
pubmed: 28237856
J Immunol. 2008 Sep 15;181(6):3733-9
pubmed: 18768823
J Immunol. 2010 Jan 1;184(1):411-9
pubmed: 19949083
Cell Death Dis. 2014 Jun 05;5:e1283
pubmed: 24901054
Parasite Immunol. 2019 May;41(5):e12621
pubmed: 30815881
J Biol Chem. 2001 Aug 24;276(34):32008-15
pubmed: 11410599
Cells. 2019 Feb 22;8(2):
pubmed: 30813369
Toxicol Lett. 2004 Nov 28;153(3):343-55
pubmed: 15454310
Pharmacol Rep. 2016 Apr;68(2):404-14
pubmed: 26922546
Chem Res Toxicol. 2003 Nov;16(11):1463-9
pubmed: 14615973
Mol Pharmacol. 2003 Jan;63(1):119-27
pubmed: 12488544
Cancer Res. 2004 Sep 15;64(18):6424-31
pubmed: 15374950
Mol Nutr Food Res. 2016 Aug;60(8):1731-55
pubmed: 27523917
Best Pract Res Clin Gastroenterol. 2010 Apr;24(2):121-32
pubmed: 20227026
Biochim Biophys Acta Mol Basis Dis. 2017 Feb;1863(2):585-597
pubmed: 27825853
J Leukoc Biol. 2013 Jun;93(6):875-81
pubmed: 23505314
Biochem Pharmacol. 1992 Mar 17;43(6):1345-51
pubmed: 1562285
J Neuroinflammation. 2016 May 03;13(1):97
pubmed: 27142843
Sci Rep. 2016 May 06;6:25525
pubmed: 27151674
J Leukoc Biol. 2017 Aug;102(2):517-525
pubmed: 28550120
Curr Cancer Drug Targets. 2006 Mar;6(2):135-45
pubmed: 16529543
Br J Dermatol. 1998 Mar;138(3):456-60
pubmed: 9580799
Cell Death Discov. 2015 Aug 24;1:15022
pubmed: 27551455
Mol Nutr Food Res. 2014 Dec;58(12):2286-96
pubmed: 25284333
Immunity. 2014 Jul 17;41(1):14-20
pubmed: 25035950
J Immunol Res. 2018 Jan 14;2018:8917804
pubmed: 29507865
Genes Dev. 1999 Jan 1;13(1):76-86
pubmed: 9887101
Trends Biochem Sci. 2014 Apr;39(4):199-218
pubmed: 24647116
J Immunol Res. 2019 Apr 14;2019:1356540
pubmed: 31111075
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Chem Biol Interact. 2017 Aug 25;274:13-23
pubmed: 28688942
Redox Biol. 2013 Jan 18;1:45-9
pubmed: 24024136
N Engl J Med. 2012 Sep 20;367(12):1087-97
pubmed: 22992072
Pharm Res. 2009 Jan;26(1):224-31
pubmed: 18841446

Auteurs

Malika Ali (M)

UVSQ, INSERM END-ICAP, Université Paris-Saclay, Versailles, France.

Marcel Bonay (M)

UVSQ, INSERM END-ICAP, Université Paris-Saclay, Versailles, France.
Service de Physiologie-Explorations Fonctionnelles, Hôpital Ambroise Paré, APHP, Boulogne, France.

Valentin Vanhee (V)

UVSQ, INSERM END-ICAP, Université Paris-Saclay, Versailles, France.

Stéphane Vinit (S)

UVSQ, INSERM END-ICAP, Université Paris-Saclay, Versailles, France.

Therese B Deramaudt (TB)

UVSQ, INSERM END-ICAP, Université Paris-Saclay, Versailles, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH